Effects of treatment with Simvastatin in elderly patients with primary hypercholesterolemia.
Atherosclerosis and its complications are the main cause of death and disability in affluent nations, especially in the elderly population. Lipids and lipoproteins play an important role in its pathogenesis. The authors treated a group of elderly patients with Simvastatin (20 mg/day for 1 year), a HMG CoA reductase inhibitor and observed a significant reduction in total cholesterol (p < 0.001). LDL (p < 0.001) and beta apolipoproteins (p < 0.05). They also achieved regression of the atherosclerotic plaque in 5 patients and arrested the atherosclerotic process in 8. The authors intend to conduct further studies in this field to better define the action of Simvastin on the atherosclerotic plaque.
Terranova
R
R
University of Catania, Chair of Geriatrics.
Luca
S
S
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019821:Simvastatin; D014463:Ultrasonography
D000924:Anticholesteremic Agents; D008148:Lovastatin; D019821:Simvastatin